Are Malignancies Increased in Uremia?

Kjellstrand, C.M.

doi:10.1159/000181627

Cited by 47 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is possible that caution should be exercised in interpreting data on CEA when the latter is measured with polyclonal kit sets. Our data showing a 5% incidence of elevated values of CEA concentrations are reasonably good in keeping with the reported inci dence of tumors in dialyzed patients [1][2][3][4][5][6][7][8][9][10][11][12]32], In fact, a 6% incidence of malignancy has been found in home dialysis patients and 2% in hospitalized patients [33], In addition, the Japanese survey detected 346 cases of can cer among 21,340 patients on dialysis, that is 1.65% [6], while the Seattle survey [8,9] detected 9 cases of cancer among 148 patients (6.1 %).…”

Section: T T T T T T T T T T T 2 0 -• • T T T T T T • •supporting

confidence: 88%

“…For ex ample, some studies do not refer to a matched control general population [2], other studies refer to death rates in the general population [8] not give the time at risk and the duration of exposure to uremia [32], But even when taking into account only the data which have been properly compared with expected cancers for exposure-and age-specific controls in the same geographical area [8,9], it is evident that in uremia the risk of cancer is higher than expected in the normal population, and especially in smokers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein

DeSanto¹,

Veneroso²,

Capodicasa³

et al. 1986

Am J Nephrol

View full text Add to dashboard Cite

The incidence of the tumor markers was studied in 140 patients aged between 18 and 84 years who had been on dialysis for 4–188 months. Neuron-specific enolase increased in 81 cases, CA-50 carbohydrate antigen in 44, while α-fetoprotein was within the normal range. Carcinoembryonic antigen (CEA) with 2 monoclonal assays was increased in 7 cases. When polyclonal assays were used, CEA was found to be elevated in 12 cases with one set and in 72 cases with another kit set. The data point (1) to the potential usefulness of these markers for the detection of malignancy and possibly neuropathy in uremia; (2) to the importance of renal tubules in the metabolism of proteins, glycoprotein and peptides, and (3) to the activation/inhibition in various enzyme systems in the uremic state.

show abstract

Section: T T T T T T T T T T T 2 0 -• • T T T T T T • •supporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein

DeSanto¹,

Veneroso²,

Capodicasa³

et al. 1986

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…On the other hand, the incidence of neoplasms in patients on hemodialysis is increased compared with the population in general [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Selenium and Haemodialysis: Serum Selenium Levels in Healthy Persons, Non-Cancer and Cancer Patients with Chronic Renal Failure

Kallistratos

Evangelou

Seferiadis

et al. 1985

Nephron

View full text Add to dashboard Cite

In 40 healthy persons, 11 nondialyzed uremic patients and 27 dialyzed uremic patients, of whom 4 also had cancer, the selenium concentration in serum was determined. The mean serum selenium concentration in healthy persons was 13.6 ± 0.8 μg/dl, in nondialyzed patients 11.9 ± 1.9 μg/dl and in dialyzed uremic patients 11.3 ± 1.0 μg/dl. There was a significant statistical difference between healthy persons and uremic patients (p < 0.00l), but not between dialyzed and nondialyzed uremic patients. The subgroup of cancer patients on hemodialysis also had low serum selenium concentrations. The possible role of low selenium levels as one of the factors responsible for the increased incidence of malignancy in patients with chronic renal failure is supported by several facts such as: (a) low serum selenium levels detected in patients with malignant diseases; (b) the higher cancer incidence in inhabitants of low-selenium areas, and (c) the known ability of selenium to inhibit many types of experimental carcinogenesis.

show abstract

“…It is well-recognized that there is an increase of malignancies in chronic uremia and in patients on chronic hemodialysis [18][19][20]; thus any effort should be made to lower the exposure of this group of patients to any possible carcinogenic drugs.…”

Section: Discussionmentioning

confidence: 99%

Androgen-Associated Hepatoma in a Hemodialysis Patient

Zevin¹,

Turani²,

Cohen³

et al. 1981

Nephron

View full text Add to dashboard Cite

A patient on hemodialysis treatment developed hepatocellular carcinoma (HCC) after long-term therapy with androgenic anabolic steroids. The tumor progressed very rapidly, and there was no evidence of regression despite discontinuation of the drug. In view of the evidence of an increased incidence of malignancy in patients with chronic uremia and hemodialysis, and of the higher frequency of HCC correlated to treatment with C17-alkylated anabolic steroids, it is necessary to further evaluate the efficiency of this treatment in the aforementioned group of patients.

show abstract

Are Malignancies Increased in Uremia?

Cited by 47 publications

References 12 publications

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein

Selenium and Haemodialysis: Serum Selenium Levels in Healthy Persons, Non-Cancer and Cancer Patients with Chronic Renal Failure

Androgen-Associated Hepatoma in a Hemodialysis Patient

Contact Info

Product

Resources

About

Are Malignancies Increased in Uremia?

Cited by 47 publications

References 12 publications

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and &alpha;-Fetoprotein

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and &alpha;-Fetoprotein

Selenium and Haemodialysis: Serum Selenium Levels in Healthy Persons, Non-Cancer and Cancer Patients with Chronic Renal Failure

Androgen-Associated Hepatoma in a Hemodialysis Patient

Contact Info

Product

Resources

About

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein

Tumor Markers in Uremia: Carcinoembryonic Antigen, Neuron-Specific Enolase, Carbohydrate Antigen CA-50 and α-Fetoprotein